AegirBio AB (publ) (OM:AEGIR) agreed to acquire LifeAssays AB (publ) (NGM:LIFE B) for approximately SEK 140 million on January 25, 2021. Under the terms of transaction, shareholders in LifeAssays AB will receive about 0.0616 shares in AegirBio AB in merger consideration for each share held. Following completion of merger, Martin Linde is expected to be CEO of new AegirBio.

The deal is subject to approval from shareholders of both the companies. If approved, merger is expected to be registered on June 1, 2021. Dennis Westermark, Monica Lagercrantz and Henrik Nobel of Lindahl Gross Lievois, P.C. acted as legal advisors to AegirBio AB.